Results 161 to 170 of about 173,364 (256)

Variation in <i>SNX29</i> and Acute Vasodilator Response in Pulmonary Arterial Hypertension. [PDF]

Circ Res
Karnes JH, Bao C, Liang S, Thayer T, Zagorski J, Naidu SR, West JD, Schwantes-An TH, Khajouei E, Banerjee K, Tiwari HK, Farol J, Martinez KL, Liu D, Ning Y, Sun Y, Jia Y, Wang J, Arora A, Batai K, Halliday SJ, Lutz K, Walsworth A, Frump AL, Rafikova O, Dai Z, Garcia JGN, Kim IM, Hemnes AR, Brittain E, Benza RL, Nichols WC, Chu A, Tang H, Desai AA.   +34 more
europepmc   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

2025 Annual Review of Pulmonary Arterial Hypertension Clinical Research. [PDF]

Pulm Ther
Nascimento IAO, Souza R, Fernandes CJCDS.   +2 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Experimental pulmonary arterial hypertension in mice with a pathogenic SOX17 variant. [PDF]

Sci Rep
Shinya Y, Hiraide T, Momoi M, Goto S, Katsumata Y, Inami T, Hakamata Y, Kataoka M, Ieda M.   +8 more
europepmc   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Prognostic Value of the RVFWLS/PASP Ratio in Pulmonary Arterial Hypertension. [PDF]

J Cardiovasc Dev Dis
Bian H, Zhao Q, Ju F, Wang L, Han Y, Qiu H, Luo C, Gang P, Li K, Ding X.   +9 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

The Role of the Apelin Receptor in the Pathophysiology of Pulmonary Arterial Hypertension. [PDF]

Cells
Rada KM, Zúniga-Muñoz AM, Alvarez-Alvarez YQ, Carbó R, Osorio-Alonso H, Zazueta C, Valle-Mondragón LD, Sánchez-Gloria JL, Guevara-Balcázar G, Rubio-Gayosso I, Sánchez-Muñoz F.   +10 more
europepmc   +1 more source

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

Epilepsia, EarlyView.
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel, Kelly G. Knupp, Boudewijn Gunning, Domenica Immacolata Battaglia, Elizabeth A. Thiele, Ingrid E. Scheffer, An‐Sofie Schoonjans, Rima Nabbout, Nathalie Villeneuve, Kerstin Alexandra Klotz, Nicola Specchio, Rocio Sanchez‐Carpintero, Marta Zolnowska, Anne‐Liv Schulz, Lily Perrin, Najla Dickson, Mélanie Langlois, Amélie Lothe, Joseph Sullivan   +18 more
wiley   +1 more source